Comparative Pharmacology
Head-to-head clinical analysis: CORTIFOAM versus FLORONE E.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTIFOAM versus FLORONE E.
CORTIFOAM vs FLORONE E
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cortifoam (hydrocortisone acetate) is a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to induce anti-inflammatory, antipruritic, and vasoconstrictive effects. It inhibits phospholipase A2, reducing prostaglandin and leukotriene synthesis, and suppresses immune cell migration and cytokine release.
FLORONE E contains diflorasone diacetate, a corticosteroid that induces phospholipase A2 inhibitory proteins (lipocortins), inhibiting arachidonic acid release and reducing prostaglandin and leukotriene synthesis, resulting in anti-inflammatory, antipruritic, and vasoconstrictive effects.
1 applicatorful (90 mg hydrocortisone acetate) rectally twice daily for 2-3 weeks, then every other day as needed.
Apply a thin film to affected skin area twice daily. Not for ophthalmic, oral, or intravaginal use.
None Documented
None Documented
Approximately 1.5-2 hours for hydrocortisone; clinically, effects persist longer due to local action.
Approximately 2-4 hours (terminal) for the active moiety diflorasone; clinically, this supports twice-daily dosing for chronic skin conditions.
Primarily renal (about 70-90% as metabolites) and fecal (about 10-30% as metabolites).
Primarily renal (<1% unchanged as metabolite) and biliary, with <1% excreted unchanged in urine. The remainder is metabolized and excreted in feces via bile.
Category C
Category C
Corticosteroid
Corticosteroid